<DOC>
	<DOCNO>NCT01436084</DOCNO>
	<brief_summary>The goal clinical research study learn SB1518 help control myelodysplastic syndrome . The safety drug also study . SB1518 design block JAK2 FLT3 . SB1518 may anti-tumor activity certain leukemia , myelofibrosis , lymphoma .</brief_summary>
	<brief_title>SB1518 Patients With Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , take SB1518 mouth 1 time every day . You take without food , take time every day . You receive monthly supply SB1518 clinic visit . The capsule open crush . Do touch powder capsule . If , wash effect area thoroughly water . Each study cycle 28 day . Study Visits : At every study visit , ask drug may take , side effect . One ( 1 ) time week Cycle 1 , blood ( 2 tablespoon ) draw routine test . On Day 1 Cycles 2 beyond , blood ( 2 tablespoon ) collect routine test . On Day 28 cycle , bone marrow aspirate and/or biopsy check status disease . If screen bone marrow test show unusual genetic test result , sample use cytogenetic testing . If response therapy , bone marrow aspirate and/or biopsy every 3 cycle , doctor think need . Length Study : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , able undergo allogeneic bone marrow transplantation , unable follow study direction . Your participation study complete end-of-treatment visit . End-of-Treatment Visit : At 30 day last dose study drug , end-of-treatment visit . - You ask drug may take , side effect . - Blood ( 2 tablespoon ) draw routine test . - You bone marrow aspirate and/or biopsy check status disease , doctor think need . This investigational study . SB1518 FDA approve commercially available . It currently use research purpose . Up 40 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>1 . Patients MDS IPSS classification include low , int1 , int2 , high risk eligible . Patients receive least one line prior therapy include growth factor , lenalidomide , hypomethylating agent . 2 . Signed informed consent . 3 . Age &gt; /= 18 year old . 4 . Patients must follow nonhematologic value : Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) &lt; /= 2.5 x Upper Limit Normal ( ULN ) available &lt; /= 5.0 x ULN hepatic involvement present determine investigator ; Serum bilirubin &lt; /=2 x ULN ; Serum creatinine &lt; /= 2 x ULN 24hour creatinine clearance &gt; /= 50 ml/min 5 . Patients , sexually active , must agree use appropriate form birth control . 1 . Uncontrolled intercurrent illness , include limited ongoing active infection psychiatric illness social situation treat physician judge would limit compliance study requirement . Patients receive antibiotic infection control may include study . 2 . History myocardial infarction , severe/unstable angina , symptomatic congestive heart failure within 6 month prior study enrollment ; 3 . New York Heart Association Class III IV congestive heart failure ; 4 . Ongoing cardiac dysrhythmias Grade &gt; /= 2 , atrial fibrillation grade , QTc prolongation &gt; 470 m factor increase risk QT prolongation ( e.g. , heart failure ; hypokalemia , define serum potassium &lt; 3.0 mEq/L ; family history long QT interval syndrome ) ; 5 . Required use concomitant medication know prolong QT interval significantly . 6 . Known HIV seropositivity ; 7 . Known active hepatitis A , B , C ; 8 . Women pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>SB1518</keyword>
</DOC>